Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology-Reference-Cited by-同舟云学术

Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology

Published:2024-01-19 Issue: Volume: Page:
ISSN:2311-3006
Container-title:Journal of Cancer Research and Practice
language:en
Short-container-title:

Author:

Chen Ming-Huang¹²,Li Wan-Shan³,Liao Bin-Chi⁴⁵,Wu Chiao-En⁶⁷,Li Chien-Feng⁸⁹,Hsieh Chia-Hsun⁷¹⁰,Kuan Feng-Che⁷¹¹,Tzeng Huey-En¹²¹³,Hang Jen-Fan²¹⁴,Chiang Nai-Jung¹²⁹,Chen Tse-Ching⁷¹⁵,Chen Tom Wei-Wu⁴⁵¹⁶,Chang John Wen-Cheng⁶⁷,Hsieh Yao-Yu¹⁷¹⁸,Chen Yen-Lin¹⁹,Yeh Yi-Chen¹⁴,Liang Yi-Hsin⁴¹⁶,Su Yu-Li²⁰,Lai Chiung-Ru¹⁴,Yang James Chih-Hsin⁴⁵¹⁶

Affiliation:

1. Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

2. School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

3. Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan

4. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

5. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan

6. Department of Hematology and Oncology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

7. College of Medicine, Chang Gung University, Taoyuan, Taiwan

8. Trans-Omic Laboratory for Precision Medicine, Chi Mei Medical Center, Tainan, Taiwan

9. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

10. Division of Hematology-Oncology, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan

11. Department of Hematology and Oncology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

12. Division of Hematology and Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

13. Ph.D. Program for Cancer Molecular Biology and Drug Discovery, and Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

14. Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

15. Department of Pathology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

16. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan

17. Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei, Taiwan

18. Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

19. Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

20. Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Abstract

Abstract Background: The Taiwan Oncology Society (TOS) and the Taiwan Society of Pathology (TSP) have collaborated to present a joint position paper on the molecular tumor boards (MTBs) within the medical institutions of Taiwan. Materials and Methods: To raise awareness of MTBs among health-care professionals, policymakers, and the public, a total of 20 experts from TOS and TSP formulated a joint consensus statement through a voting process. Results: The joint statement proposes key recommendations: (1) MTB discussions encompass diverse molecular analyses including next-generation sequencing (NGS), RNA sequencing, whole-exon sequencing, and whole-genomic sequencing addressing relevant genomic changes, tumor mutation burden, microsatellite instability, and specific biomarkers for certain cancers. (2) MTB meetings should involve multidisciplinary participants who receive regular updates on NGS-related clinical trials. (3) Prioritize discussing cases with unique clinical needs, gene alterations lacking treatments, untreatable neoplasms, or oncogenes unresponsive to targeted therapies. (4) Base MTB discussions on comprehensive patient data, including genetics, pathology, timing of specimen collection, and NGS outcomes. (5) MTBs offer treatment recommendations: standard therapies, off-label use, clinical trials, genetic counseling, and multidisciplinary reviews. (6) MTB effectiveness can be gauged by member composition, case reviews, treatment suggestions, and patient outcomes. Encourage government incentives for MTB engagement. Conclusion: The primary aim of this initiative is to promote the advancement of precision oncology in Taiwan.

Publisher

Medknow

Subject

General Medicine

Reference25 articles.

1. Standards and guidelines for the interpretation and reporting of sequence variants in cancer:A Joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists;Li;J Mol Diagn,2017

2. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy;Kato;Nat Commun,2020

3. Molecular tumor boards in clinical practice;Luchini;Trends Cancer,2020

4. Determining accurate costs for genomic sequencing technologies-a necessary prerequisite;Jegathisawaran;J Community Genet,2020

5. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research;Belli;Ann Oncol,2021